BACK

Mark Simon

Mark Simon

Partner and Co-Founder

New York Office  |  mark.simon@torreya.com   |   212.257.5809

Mark Simon, Torreya Partner and Co-Founder, heads the Biotech Advisory Team and participates in many of the firm’s biotech, pipeline, and specialty pharma transactions. He has expansive scientific and clinical knowledge across multiple therapeutic areas. In 30 plus years of advising biotech and specialty pharma companies, he has worked on more than 175 financing and M&A transactions totaling over $50 billion in value.

Before co-founding Torreya in 2007, Mark was a Managing Director and the Head of Life Sciences Investment Banking at Citigroup, where he covered global pharmaceutical companies, with a focus on large-capitalization players in the US, Europe, and Japan. Prior to his tenure at Citigroup, Mark served as a Managing Director at Robertson Stephens in San Francisco and New York. There, he was involved in raising 45% of all biotech dollars raised in the US from 1999-2001.

Before moving into investment banking, Mark was a Senior Biotech Research Analyst at Robertson Stephens, where he was named Wall Street All-Star Analyst three years in a row. He began his career as a Research Associate at Kidder Peabody in New York in 1984, covering biotechnology and health care services companies.

Mark holds a B.A. in history from Columbia College and an M.B.A. from Harvard Business School.

He is Senior Advisor to the Milken Family Foundation’s Prostate Cancer Foundation and a Director of the Alliance for Aging Research.

Selected Transactions

Mallinckrodt Pharmaceuticals
Sale of
Intrathecal business to
Piramal
$203 million
March 2017
XOMA
License of global rights
for Anti-TGF-beta
antibody program to
Novartis
Up to $517 million
October 2015
cCam Biotherapeutics
Sale to
Merck
Up to $605 million
July 2015
Phenex
Sale of FXR program to
Gilead
Up to $470 million
January 2015
Chelsea Therapeutics
Sale to
Lundbeck
$658 million
June 2014
Xoma
Acquires royalty interest position for 7 assets from
Agenus
$15 million
September 2018
EyePoint Pharmaceuticals
Debt financing for acquisition of Icon Biosciences from
SWK Holdings
$20 Million
March 2018
XOMA
License of
Gevokizumab and
certain associated IP to
Novartis
$31 million upfront
August 2017
Essential Pharmaceuticals
Asset sale to
Accord
Undisclosed
July 2017
Assembly Biosciences
Microbiome partnership with
Allergan
$2.6 billion
($50 million upfront)
January 2017
XOMA
Sale of royalties to
Healthcare Royalty Partners
$22 million
December 2016
PhosImmune
Sale to
Agenus
Up to $45 million
($16 million upfront)
December 2015
XOMA
Sale of
biologics manufacturing
facilities to
Agenus
$5 million in cash +
$1 million in stock
November 2015
PDI
Acquisition of
Redpath Integrated Pathology
Up to $35 million
October 2014
CureTech
License of Pidilizumab to
Medivation
Up to $335 million
with royalty
October 2014
Compugen
Financial advisor on
follow-on offering
Undisclosed
$72.5 million
February 2014
4-Antibody AG
Sale to
Agenus
$40+ million with
$10 million upfront
January 2014
Pinnacle Biologics
Sale to
Concordia Healthcare
Undisclosed
December 2013
Correvio
Sale to
Cardiome
19.9% of shares +
$12 million
November 2013
Compugen
Advisor on oncology partnership with
Bayer
$550 million with
$10 million upfront
August 2013
Molecular Insight
Sale for up to
$106 million to
Progenics
$12 million +
milestones
January 2013
GTx
Sale of Fareston® to
Prostrakan/Kyowa Hakko Kirin
$21.7 million
October 2012
Xanodyne
Sale of
Amicar® rights to
Versapharm
Undisclosed
August 2012
Xanodyne
Sale of
Roxicodone® to
Covidien
Undisclosed
August 2012
Xanodyne
Sale of Zipsor® to
Depomed
Undisclosed
June 2012
Xanodyne
Co-promotion for
Zipsor®
Medimetriks
Undisclosed
May 2011
GTCR
Advisor in the acquisition of six products from
UCB
Undisclosed
July 2010
Shareholder Group
Advisor to Genentech
major shareholder
in sale to
Roche
$46 billion
March 2009
ProEthic Pharma
Sale to
Kowa Pharmaceuticals
Undisclosed
April 2008